Literature DB >> 11979456

CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory.

Thorsten Langer1, Peter Martus, Holger Ottensmeier, Holger Hertzberg, Jörn D Beck, Walburga Meier.   

Abstract

PURPOSE: To date, the event free survival (EFS) after treatment of childhood acute lymphoblastic leukemia (ALL) attains 80%. The survivor group is growing steadily. Therefore, the primary purpose of our study is to define the neuropsychological function and to describe which central nervous system (CNS) functions are impaired following the German ALL-BFM and COALL protocols for CNS-negative patients. PATIENTS AND METHODS: In a cross-sectional multicenter study 121 subjects, long-term survivors of childhood ALL in first continuous complete remission were investigated. Seven years ago, the subjects were treated as standard or medium risk patients according to ALL-BFM 81, ALL-BFM 83, or COALL 82 protocols, receiving comparable treatments. According to different CNS-prophylaxes, two subgroups were compared in the study: the non-cranially irradiated MTX-group (methotrexate-group) (n = 38) and the cranially irradiated RT-group (radiotherapy-group) (with MTX i.th.) (n = 83). Intellectual and cognitive abilities of these groups were evaluated using standardized psychometric techniques. The Kaufman factors Verbal Comprehension, Perceptual Organisation and Freedom from Distractibility were calculated. Demographical and clinical data collected at the time of the diagnosis were compared between both groups. The different prognoses for patients within both groups were taken into account using a defined risk factor. Analysis of variance was conducted to relate intellectual performance to age, gender, and CNS-treatment.
RESULTS: The RT-group exhibited a lower Full Scale IQ than the MTX-group (101.2 +/- 15.9 vs. 109.9 +/- 14.9, P = 0.031). Particularly for the Kaufman factor Freedom from Distractibility the RT-group showed the lower scores (96.9 +/- 14.1 vs. 105.5 +/- 12.6, P = 0.037). Significant interactions between gender and CNS prophylactic treatment were observed for Full Scale IQ (P = 0.008), Verbal IQ (P = 0.012), Performance IQ (P = 0.024), Verbal Comprehension (P = 0.004), and Perceptual Organisation (P = 0.032).
CONCLUSIONS: Cranial irradiation in combination with MTX therapy was associated with deficits in attention, concentration, and the ability of sequencing and processing, measured by the Kaufman factor Freedom from Distractibility. Our results support the strategy of avoiding prophylactic CNS irradiation in low risk patients. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979456     DOI: 10.1002/mpo.10055

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  46 in total

1.  Adolescent cancer survivors' smoking intentions are associated with aggression, attention, and smoking history.

Authors:  Lisa S Kahalley; Vida L Tyc; Stephanie J Wilson; Jenna Nelms; Melissa M Hudson; Shengjie Wu; Xiaoping Xiong; Pamela S Hinds
Journal:  J Cancer Surviv       Date:  2010-10-05       Impact factor: 4.442

2.  Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review.

Authors:  Yin Ting Cheung; Kevin R Krull
Journal:  Neurosci Biobehav Rev       Date:  2015-04-07       Impact factor: 8.989

3.  Are the psychological needs of adolescent survivors of pediatric cancer adequately identified and treated?

Authors:  Lisa S Kahalley; Stephanie J Wilson; Vida L Tyc; Heather M Conklin; Melissa M Hudson; Shengjie Wu; Xiaoping Xiong; Heather H Stancel; Pamela S Hinds
Journal:  Psychooncology       Date:  2012-01-25       Impact factor: 3.894

Review 4.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

5.  Therapeutic doses of cranial irradiation induce hippocampus-dependent cognitive deficits in young mice.

Authors:  Amulya A Nageswara Rao; Hong Ye; Paul A Decker; Charles L Howe; Cynthia Wetmore
Journal:  J Neurooncol       Date:  2011-04-17       Impact factor: 4.130

6.  Feasibility of neuropsychological assessment in leukaemia patients shortly after diagnosis: directions for future prospective research.

Authors:  N C Jansen; A Kingma; P Tellegen; R I van Dommelen; A Bouma; A Veerman; W A Kamps
Journal:  Arch Dis Child       Date:  2005-03       Impact factor: 3.791

7.  Evaluation of memory impairment in aging adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiotherapy.

Authors:  Gregory T Armstrong; Wilburn E Reddick; Ronald C Petersen; Aimee Santucci; Nan Zhang; Deokumar Srivastava; Robert J Ogg; Claudia M Hillenbrand; Noah Sabin; Matthew J Krasin; Larry Kun; Ching-Hon Pui; Melissa M Hudson; Leslie L Robison; Kevin R Krull
Journal:  J Natl Cancer Inst       Date:  2013-04-12       Impact factor: 13.506

8.  Slower processing speed after treatment for pediatric brain tumor and acute lymphoblastic leukemia.

Authors:  Lisa S Kahalley; Heather M Conklin; Vida L Tyc; Melissa M Hudson; Stephanie J Wilson; Shengjie Wu; Xiaoping Xiong; Pamela S Hinds
Journal:  Psychooncology       Date:  2013-02-28       Impact factor: 3.894

9.  Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.

Authors:  Nina S Kadan-Lottick; Pim Brouwers; David Breiger; Thomas Kaleita; James Dziura; Veronika Northrup; Lu Chen; Megan Nicoletti; Bruce Bostrom; Linda Stork; Joseph P Neglia
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

10.  Health-related quality of life and cognitive outcomes among child and adolescent survivors of leukemia.

Authors:  Shyh-Shin Chiou; Ren-Chin Jang; Yu-Mei Liao; Pinchen Yang
Journal:  Support Care Cancer       Date:  2009-12-01       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.